ImmuCell

ICCC

Market cap $57.7M

ICCC's 2025 sales rise 4.3% y/y, with the gross margin expanding sharply, helping narrow its annual net loss despite asset write-downs and strategic shifts.

ImmuCell Corporation (ICCC) Q4 2025 Earnings Call Transcript

PORTLAND, Maine, March 04, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced its unaudited financial results for the year ended December 31, 2025.

PORTLAND, Maine, Feb. 18, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, expects to report unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, March 4, 2026. The Company is planning to host a conference call the next morning, Thursday, March 5, 2026, at 9:00 AM ET to review the unaudited financial results.

CPIX, NAII and ICCC lean into specialization, compliance and targeted growth to thrive in the niche healthcare markets.

ImmuCell Corporation (ICCC) Q4 2025 Sales/Trading Call Transcript

PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025.

PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense ® product line and away from Re-Tain ® on December 24, 2025.

PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain ® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense ® field sales force by 50% and expanding its First Defense ® manufacturing capabilities.

ICCC's innovative, antibiotic-free cattle health products drive margin recovery, real-world adoption and stock gains.